Better Health for All

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for serious diseases with no currently available therapeutic options, such as X-linked retinitis pigmentosa (XLRP), Parkinson's disease, achromatopsia, Leber congenital amaurosis, pediatric obesity, and ALS.

Clinical trials for XLRP and Parkinson's disease have demonstrated significant, clinically meaningful improvements in vision, motor function, and quality of life for patients. The company's entire business model is dedicated to these health-improving gene therapies, with no evidence of harmful products. The company commits substantial resources to R&D, with $32.8 million in Q1 2025 and $34.9 million in Q2 2024 , and a $230 million commitment to a joint venture for AAV-GAD development. Safety records for clinical trials indicate that treatments are generally safe and well-tolerated; AAV-GAD for Parkinson's showed no serious adverse events (SAEs) related to treatment in 14 subjects , and botaretigene sparoparvovec for XLRP had 3 SAEs in 45 patients, mostly related to surgical procedures and resolving without intervention. The company's Code of Conduct requires reporting of known or suspected violations and disclosure of potential conflicts of interest, and it operates an Ethics Hotline available 24/7, allowing anonymous reporting. The company states a commitment to avoiding adverse environmental impact and injury to communities, but provides no specific metrics. While the company states a commitment to equal opportunity and fair treatment, there is no explicit evidence of specific health equity programs or initiatives to strengthen healthcare workforce capacity. The company maintains a drug-free workplace policy, but this is not a preventative health measure for the general public. The company safeguards confidential information and reserves the right to monitor electronic and telephonic communication, but lacks specific details on health data privacy safeguards. Clinical trials are conducted under extensive regulation by the FDA and EMA , and the company has treated children in trials for XLRP and LCA4 , and XLRP primarily affects males.

Fair Pay & Worker Respect

As of December 31, 2024, none of the company's 381 employees were subject to a collective bargaining agreement or represented by a trade or labor union.

All full-time employees, including named executive officers, are eligible to participate in health and welfare plans, subject to the same terms and eligibility requirements. The company matches 100% of employee contributions to its 401(k) plan, up to 6% of eligible compensation. Employee engagement, based on Glassdoor reviews, is rated 2.8 out of 5 stars, which is 20% below the industry average. Only 34% of employees would recommend working at the company.

Fair Trade & Ethical Sourcing

No relevant data regarding fair trade or ethical sourcing practices was found in the provided article to assess the company against the specified KPIs.

The article explicitly states that no data could be extracted from the linked governance documents.

Kind to Animals

MeiraGTx is discussing the use of AI analysis of imaging data with the FDA to support labeling claims for AAV-GAD in Parkinson's disease, indicating some use of non-animal methods, though the extent is not specified.

The company's R&D expenses were $33.5 million for the three months ended June 30, 2025, and it is investing in a riboswitch technology platform and collaborating with Hologen AI, but no specific percentage of the R&D budget is allocated to animal-free technologies. MeiraGTx is engaged with the FDA and MHRA regarding multiple clinical programs and manufacturing, which suggests advocacy for specific welfare standards and participation in regulatory consultations.

Planet-Friendly Business

No specific, concrete evidence was found in the provided articles for any of the Planet-Friendly Business KPIs. The articles primarily focus on financial performance, clinical development, regulatory approvals for drug manufacturing, and general industry trends, rather than the company's environmental stewardship, emissions, renewable energy use, waste management, or climate-related disclosures.

Information about industry averages or general regulatory environments is not considered direct evidence of the company's specific performance against the KPIs.

Safe & Smart Tech

The company has not experienced any material cybersecurity breaches to its knowledge as of December 31, 2024.

It maintains a cybersecurity risk management program based on the Center for Internet Security (CIS) Controls standard and the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF). This program includes risk assessments, security controls, an IT and security team, external service providers, cybersecurity awareness training, and an incident response plan. The Board's Audit Committee oversees cybersecurity risks and receives semi-annual reports from management. The company has a strong compliance program, evidenced by successful renewals of MHRA and HPRA manufacturing licenses in 2024 and 2025, and a clean FDA Good Clinical Practice (GCP) inspection in July 2025 with zero observations. It is subject to and works to comply with various data privacy and protection regulations, including HIPAA, CCPA, GDPR, and UK GDPR. The company has a formal vulnerability disclosure program, but no specific details on its responsiveness or scope are provided.